A Phase 2 interventional study of SAFETY-A within usual ED Care and Combined SAFETY-A within usual ED Care + CLASP Therapeutic Follow-Up Contacts in Suicide, Suicidal and Self-Harm, sponsored by University of California, Los Angeles. Recruiting at 5 sites in United States. Open to participants aged 13 Years to 24 Years. Per ClinicalTrials.gov, last updated 2025-12-31.
Sponsored by University of California, Los Angeles · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 387 studies in Suicide with a site in United States — 100 open to participants now, 114 under way, 2 of them phase 3. Suicide · United States.
Among the 387 studies in Suicide with a site in United States, this one is the 27th largest by planned enrollment of the 349 interventional ones that give a count, is one of 45 that started in 2022, is one of 18 in phase 2, reaches primary completion later than 26 of the 113 other live ones, and was the 247th registered.
609 studies on the registry are indexed under Suicide; 163 are open to participants now.
Browse Suicide studies →100 of the 387 studies in Suicide with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States
Ages 12–80
Albert Einstein College of Medicine · Sites in United States
Ages 14–18
University of California, San Diego · Sites in United States
Ages 12–30
VA Office of Research and Development · Sites in United States
Ages 18+
University of Pennsylvania · Sites in United States
Ages 13–17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 114 Suicide studies recruiting now, 55 (48%) set no upper age limit and 56 (49%) stop at 75 or younger; 52 take children under 18; 25 take healthy volunteers.
This study: 13 Years to 24 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
387 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 30 · Phase 3 10 · Phase 4 11
First in 1990; this study’s year is marked. 45 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,600 is above the median of 104 across 492 interventional studies indexed under Suicide.
Median enrollment 91 across the 349 interventional studies, 172 across the 36 observational. Of the 251 that completed or were terminated, 103 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 387 have an industry lead sponsor. The 10 most frequent:
University of California, Los Angeles is the lead sponsor of 1,172 studies on the registry; 195 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 70 (74%) have results posted.
University of California, Los Angeles has 3 studies filed under Suicide — fewer than ten, so there is no comparison to draw.
44 of the studies in Suicide with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05696691Phase 3The University of Texas Health Science Center at San AntonioKetamine & Crisis Response Plan for Suicidal Ideation in the ED | 2026-12-31 |
| NCT05558332University of California, IrvineYouth Nominated Support Team | 2026-11 |
| NCT06470867VA Office of Research and DevelopmentRandomized Controlled Effectiveness Trial of VA S.A.V.E. | 2026-11-27 |
| NCT05897164Evidence-Based Practice Institute, Seattle, WAMobile Technology to Reduce Teen Substance Misuse | 2026-11-30 |
| NCT06460220Jennifer HughesSAFETY-Parent: Online Learning Module to Support Parents of Suicidal Youth | 2026-12 |
Add all 44 to your calendar (.ics) → With an account.
Among the 387 studies in Suicide with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized comparative effectiveness trial will compare two evidence-based approaches to emergency care for youth ages 13-24 who present to the Emergency Department (ED) with suicidal ideation or behavior. Outcomes will be monitored at baseline and at 3, 6 \& 12 month follow-up assessments.
Rationale and Importance of Study:
Suicide is currently the second leading cause of death for U.S. youth ages 13-24, responsible for more deaths than any major illness. Youth with serious suicidal behavior or thoughts often present to the nation's Emergency Departments (EDs), particularly youth who make potentially deadly suicide attempts. Evidence is limited regarding optimal interventions for reducing the risk of fatal and nonfatal suicide attempts in these youth, and tested interventions include multiple components. One dimension along which these interventions vary is timing. Some interventions are delivered in the ED, others focus on aftercare, and others combine ED and aftercare interventions. Current evidence supports effectiveness of some interventions for reducing later suicide attempts and improving the likelihood that youth will receive mental health treatment after leaving the ED. However, evidence gaps exist regarding: 1) whether it is sufficient to focus on providing an evidence-based intervention in the ED, or whether a post-ED aftercare intervention is needed to improve youth outcomes; and 2) for which patient subgroups a combined ED and aftercare treatment may be indicated. Answering these questions is vital for guiding resource allocation, as ED care emphasizes care in the ED with limited resources for aftercare.
Study Aims:
The study addresses this evidence gap by comparing two evidence-based interventions for reducing suicide attempts and improving outcomes for youth presenting to EDs with suicidal episodes: 1) Safety-Acute(A) integrated within ED care, a crisis therapy/safety planning intervention in the ED focused on enhancing safety (previously called Family Intervention for Suicide Prevention, FISP); and 2) SAFETY-A/ED care plus the Coping Long-term with Active Suicide Program (CLASP), comprised of brief therapeutic follow-up contacts after discharge from the ED/hospital. Evidence supports benefits of both interventions individually. SAFETY-A/FISP is listed in the National Register of Evidence-Based Practices, and CLASP is being implemented in some Veterans Administration Hospitals. The first aim is to evaluate whether SAFETY-A/ED Care combined with CLASP aftercare is superior to SAFETY- A/ED Care alone for reducing the risk of suicide attempts and increasing initiation of follow-up mental health treatment. Second, the investigators examine heterogeneity of treatment effects among subgroups, hypothesizing that in this large diverse sample the strongest benefits of the combined SAFETY-A/ED Care plus CLASP intervention will be seen in youth who are from ethnic or racial minority groups, socioeconomically disadvantaged, and from rural communities. Third, the investigators aim to increase the value and relevance of the study by engaging patients, parents, family members, providers, and health and mental healthcare system stakeholders in project leadership and activities throughout the study and implement a partnered dissemination plan to enhance the potential for study findings to inform clinical practice and health care delivery.
Study Description:
The patient population includes 1,600 youth ages 13-24 presenting to EDs with suicidal ideation or behavior in 4 communities across the country selected to include a diverse population (racial, ethnic, rural vs urban, public vs private insurance): California/Los Angeles; North Carolina; Rhode Island; Utah. Youth are randomly assigned to: 1) SAFETY-A/ED Care; or 2) SAFETY-A/ED Care plus CLASP. Assessments are conducted at the start of the study and at 3, 6, and 12-month follow-ups. Primary outcomes are suicide attempts and mental health treatment initiation. Secondary outcomes are overall self-harm (including suicide attempts and non-suicidal self-harm) and treatment engagement/dose. Exploratory outcomes are: severity of youth suicidality; youth functioning and quality of life; and improvement on three problems prioritized by the youth and parent or significant other as "top problems." The investigators also examine change in identified protective and risk factors (e.g. connectedness, hopelessness, and perceived barriers to treatment). The investigators partner with diverse stakeholders, develop a Stakeholder Council, and include stakeholder partners in project leadership and activities with the goals of promoting 2-way knowledge exchange and enhancing the value of the study for improving patient care and outcomes.
Significance:
Study results will clarify whether the additional resources needed to provide brief therapeutic follow-up calls after an ED intervention leads to improved outcomes, and which patient subgroups are most likely to benefit from a treatment approach that provides therapeutic contact both during the ED visit and after discharge from the ED. This information can guide decision makers regarding how to best develop services and service systems to improve patient outcomes and achieve national suicide prevention goals, including for diverse groups to improve equity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The SAFETY-Acute (A) approach to safety planning and stabilization will be integrated within usual ED Care. SAFETY-A was formerly called the Family Intervention for Suicide Prevention, FISP.
Behavioral: SAFETY-A within usual ED Care
The combined treatment arm includes both 1) SAFETY-A integrated within usual ED Care, and 2) therapeutic follow-up contacts using the Coping Long Term with Active Suicidality Program (CLASP) model.
Behavioral: Combined SAFETY-A within usual ED Care + CLASP Therapeutic Follow-Up Contacts
SAFETY-A is a single session collaborative, strengths-based, developmentally nuanced, cognitive-behavioral intervention (CBT) to increase safety and mental health treatment initiation. The therapist works with the youth and family (or significant other, SO) separately and together to build hope and reasons for living, develop a personal safety plan, increase protective supports; and increase motivation for and linkage to treatment.
Also known as: Family Intervention for Suicide Prevention (FISP)
COMB, includes SAFETY-A within usual ED care plus CLASP therapeutic and caring follow-up contacts designed to strengthen safety and treatment initiation and engagement. Core functions of CLASP include: building hope/reducing hopelessness; enhancing social/family support; strengthening problem-solving; and increasing treatment initiation and engagement.
Suicide Attempts: Primary Clinical Outcome
suicide attempts fatal, nonfatal, and interrupted
Time frame: Through 12 months of follow-up
Mental Health Treatment Initiation: Primary Service Use Outcome
initiation of mental health treatment after discharge from ED/hospital
Time frame: Observed through 12 months of follow-up, primary end point 6-month follow-up
Self-Harm: Secondary Clinical Outcome
Any self-harm including suicidal, nonsuicidal, and ambiguous self-harm
Time frame: Through 12 months of follow-up
Treatment engagement: Secondary Service Use Outcome
Treatment dose received
Time frame: Through 12 months of follow-up
Ordinal suicidality scale: Clinical
Ranges from nonsuicidal through ideation, behavior, attempts, and deaths
Time frame: Through 12 months of follow-up
Quality of life and functioning: Clinical
PROMIS Global Health Questionnaire , 0-100
Time frame: Change from baseline through 12 months of follow-up
Plan to share: Yes — Decision will be made with PCORI, project investigators, and stakeholders regarding any data sharing. Given relative rarity of suicide attempts it is critical that participant confidentiality be maintained and steps be taken to protect against the possible of unintended loss of anonymity due to focus on rare outcome.
Supporting information: Study protocol
Time frame: A limited data set may be available after all data are complete, analyzed, and published. Time frame and plan will be developed by investigators in collaboration with stakeholders and funding agency (PCORI).
Access criteria: Decision will be made with PCORI, project investigators, and stakeholders regarding any data access. Given rarity of suicide attempts it is critical that participant confidentiality be maintained and steps be taken to protect against the possibility of unintended loss of anonymity due to focus on rare outcomes.
Started Oct 2022 (actual). Primary completion is estimated for Dec 2026, 50 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, Los Angeles →